A5040841197- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- Gastrointestinal Tumor Research and Treatment
- Medical Device Sterilization and Disinfection
- Nutrition and Health in Aging
- Gestational Trophoblastic Disease Studies
- Esophageal Cancer Research and Treatment
- Neuroblastoma Research and Treatments
- Gastric Cancer Management and Outcomes
- Childhood Cancer Survivors' Quality of Life
Sapienza University of Rome
2022-2024
Azienda Ospedaliera Sant'Andrea
2022-2024
Objectives: Our aim was to investigate the clinical outcome of patients with well-differentiated gastric, duodenal, and rectal neuroendocrine tumors after treatment incomplete endoscopic resection due finding microscopic positive margins (R1). Methods: This is a retrospective analysis consecutive type 1 non-ampullary non-functioning or neoplasms R1 resection. The rate tumor recurrence progression-free survival were considered be study's main endpoints. Statistical performed using MedCalc®...
Background: Neuroendocrine neoplasms (NENs) are slow-growing tumors. Sarcopenia is defined as the loss of muscle mass, strength, and physical performance. First-line NEN therapy somatostatin analogs, which could be responsible for malabsorption conditions, such pancreatic exocrine insufficiency (EPI) with underlying sarcopenia. Aim: Evaluate prevalence sarcopenia in patients NENs at diagnosis during follow-up. Methods: A retrospective single-center study was conducted, including advanced...
Gastric neuroendocrine neoplasms (g-NENs) are rare tumors arising from the gastric enterochromaffin-like cells. Recent data suggests an increased detection rate, attributed to more frequent esophagogastroduodenoscopies. While type 3 g-NENs were historically deemed aggressive, emerging research indicates potential for conservative management, especially endoscopic resection, in well-differentiated, small tumors. European guidelines now advocate intervention selected cases, but North American...
Aims To develop and validate a new scale for mucosal visualization of the upper gastrointestinal tract during esophagogastroduodenoscopy (EGD), Gastroscopy RAte Cleanliness Evaluation (GRACE), as quality standard tool through application standardized, reliable, validated scoring system.
Aims Endoscopic resection margin R1 (ER1) describes neoplasia presence at lateral and/or deep margin. Highest rate of occurs in duodenal NENs (d-NENs) where advanced techniques [endoscopic submucosal dissection (ESD); full thickness (EFTR)], are more difficult to apply. In gastric (g-NENs) and rectal (r-NENs), due favorable anatomy, ESD or EFTR obtain lower rates resection. Aim the study is assess endoscopic recurrence/progression risk site pts with gastric, undergone ER1.